Researchers at the University Medical Center Mainz develop drug against fatty liver hepatitis

Innovative fatty acid proves highly effective and well tolerated in clinical trial

Scientists of the Institute of Translational Immunology at University Medical Center Mainz have co-developed a novel drug that could effectively treat non-alcoholic fatty liver inflammation: the modified omega-3 fatty acid icosabutate. In the ongoing phase 2b clinical trial „ICONA“, the positive results seem to be confirmed: The compound prevented inflammation and scarring of the liver. To date, there is no established therapy and no approved drug for non-alcoholic fatty liver inflammation.

Quelle: IDW Informationsdienst Wissenschaft